Cannabics Pharmaceuticals Inc. (CNBX) – Developing Novel Therapies to Answer Medical Needs

When used for medicinal purposes, cannabis can have a number of beneficial effects from appetite stimulation to pain relief. Cannabinoids, which can serve as pain relievers, could therefore be used as (or in) medicine for cancer patients. Millions of patients could benefit from the therapeutic effects of these compounds, especially those seeking safe, regulated, easy to administer cannabis-based therapies.

Cannabics Pharmaceuticals is committed to meeting unmet medical needs and designing leading-edge technologies in the field of cannabinoid-based therapies. The company’s research and development efforts are presently focused on the:

•           development of administration routes of active cannabinoids

•           identification of the interactive, beneficial therapeutic effects of assorted cannabis-based compounds in varied indications

•           development of personalized cannabinoid therapies for cancer patients

Through research, Cannabics has collected precious knowledge about the effectiveness of cannabis strains as therapies for specific symptoms. The company continues to develop its genetic and phenotipic database in order to provide better treatments for incapacitating and incurable ailments.

Cannabics’ stated objective is to be one of the first (and few) companies in the world to commercialize cannabis-based medical products that are indication-specific and have been clinically tested. To reach this goal, Cannabics is currently preparing for the launch of a series of rigorously controlled clinical studies in leading medical centers in Israel, where the company’s research and development division is based.

Cannabics Pharmaceuticals is an emerging drug development company that is employing novel technologies in order to develop innovative cannabinoid-based therapies for a range of debilitating ailments. The company is focused on developing and marketing advanced drugs, therapies, food supplements and administration routes based on active ingredients found in strains of the cannabis plant. Cannabics’ flagship product is Cannabics SR, a slow-release medical cannabis capsule designed as a pain-relieving therapy for cancer patients.

For more information, visit the company’s website at www.cannabics.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net